DelveInsight’s “Pertussis – Pipeline Insight, 2026” report provides an extensive analysis of more than 10 companies and over 10 investigational drugs actively shaping the Pertussis treatment pipeline. The report encompasses detailed drug profiles spanning both clinical and preclinical development stages, offers therapeutic assessments categorized by product type, development phase, route of administration, and molecular classification, and identifies inactive pipeline candidates within the Pertussis space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Pertussis Treatment Landscape @ Pertussis Pipeline Insight Report
Key Highlights from the Pertussis Pipeline Report
- DelveInsight’s Pertussis pipeline analysis reveals a dynamic development landscape with more than 10 active companies progressing over 10 therapeutic candidates aimed at Pertussis prevention and treatment.
- Leading Pertussis Companies include Tianjin CanSino Biotechnology, ILiAD Biotechnologies, LG Chem, BioNet-Asia, Intravacc, VAXFORM LLC, and other key organizations actively advancing novel approaches in this space.
- Companies with drug candidates in the most advanced stages of development—specifically Phase III—include Tianjin CanSino Biotechnology and others.
- Therapies currently under investigation are centered on innovative strategies designed to provide more durable, effective, and broadly accessible protection against Bordetella pertussis infection and whooping cough disease.
- Pharmaceutical companies and academic institutions are collaboratively working to identify challenges and uncover opportunities that could meaningfully influence Pertussis research and development.
Stay informed about the cutting-edge advancements in Pertussis treatments. Download for updates and be a part of the revolution in Infectious Disease Care @ Pertussis Clinical Trials Assessment
Pertussis Disease Overview
Pertussis, commonly referred to as whooping cough, is a highly contagious respiratory illness caused by the Gram-negative coccobacillus bacterium Bordetella pertussis. While it predominantly affects infants and young children, adolescents and adults are also susceptible. The disease is distinguished by severe, prolonged coughing episodes that can persist for weeks or even months. Despite the availability of effective vaccines, pertussis continues to pose a significant public health challenge due to periodic outbreaks and the gradual decline of vaccine-induced immunity over time.
Clinical Stages
The clinical course of pertussis unfolds across three distinct phases:
1. Catarrhal Stage (1–2 weeks): Resembles a common upper respiratory infection, presenting with nasal congestion, mild fever, and a mild cough. This stage is the most infectious period but is often difficult to distinguish from other respiratory illnesses.
2. Paroxysmal Stage (1–6 weeks): Characterized by intense, rapid coughing fits that may culminate in a distinctive high-pitched “whoop” sound upon inhalation. These episodes can trigger vomiting, extreme exhaustion, and potentially serious complications including pneumonia.
3. Convalescent Stage: Involves gradual recovery, although residual coughing may linger for months during the recuperation period.
Pathophysiology
Bordetella pertussis attaches to the cilia lining the respiratory epithelial cells, releasing toxins that paralyze ciliary function and trigger inflammation throughout the respiratory tract. This process disrupts the normal clearance of pulmonary secretions. The pertussis toxin plays a particularly critical role by elevating cyclic AMP levels within host cells, producing a cascade of systemic effects. The bacterium disseminates through respiratory droplets generated by coughing or sneezing from infected individuals. Due to its exceptionally high infectivity, pertussis can propagate rapidly, especially within communities with insufficient vaccination coverage.
Diagnosis
Diagnosing pertussis presents considerable challenges, particularly during the early catarrhal stage when symptoms closely mirror other respiratory infections. Clinical diagnosis is frequently based on the characteristic whooping cough pattern and documented exposure history. Laboratory confirmation is typically achieved through nasopharyngeal swabs, with polymerase chain reaction (PCR) representing the most sensitive diagnostic method. Bordetella pertussis culture remains an alternative but offers lower sensitivity and requires extended processing time. Serological testing can provide supplementary diagnostic value, particularly for detecting antibodies during later disease stages.
Current Treatment Approaches
The primary therapeutic intervention for pertussis involves antibiotic therapy, with macrolide antibiotics (azithromycin, clarithromycin, or erythromycin) serving as first-line agents. Early treatment initiation can reduce symptom severity and duration while decreasing disease transmission. Supportive care—including adequate hydration and supplemental oxygen therapy—may be required for severe cases, particularly in infants.
Vaccination remains the most effective prevention strategy against pertussis. The DTaP (diphtheria, tetanus, and acellular pertussis) vaccine is administered to children through a multi-dose series, while the Tdap booster is recommended for adolescents and adults. Pregnant women are advised to receive Tdap vaccination during each pregnancy to confer passive protection to newborns. Despite ongoing vaccination efforts, continuous monitoring and timely booster administration remain essential for maintaining community-level immunity.
Learn how the Pertussis market will evolve and grow in the coming years @ Pertussis Market Outlook and Forecast
Spotlight on Emerging Pertussis Drug Candidates
DTcP Infant – Tianjin CanSino Biotechnology
DTcP Infant is a potential best-in-class diphtheria, tetanus, and acellular pertussis (component) vaccine for primary infant vaccination in China, under development by Tianjin CanSino Biotechnology. Unlike currently available co-purified DTaP vaccines manufactured in China, DTcP Infant employs an advanced production process in which each pertussis antigen is individually purified and formulated in a precisely defined ratio, ensuring superior batch-to-batch consistency and enhanced product stability.
As of the latest reporting period, no domestically manufactured component-based DTaP vaccine has received marketing approval in China, positioning DTcP Infant as a compelling alternative to imported vaccines. Additionally, the development of DTcP Infant establishes a robust foundation for the subsequent advancement of Tdcp Adolescent and Adult formulations, as well as the CS-2201 DTcP components combined vaccine.
In August 2023, the Phase III clinical trial for DTcP Infant was officially initiated with formal enrollment of the first trial participant. The company anticipates commencing pre-NDA processes in 2025. DTcP Infant is currently in Phase III of clinical development for pertussis prevention.
BPZE1 – ILiAD Biotechnologies
BPZE1 is a next-generation, live-attenuated pertussis vaccine engineered to induce comprehensive and long-lasting protection against both B. pertussis infection (colonization) and disease (whooping cough). Developed by ILiAD Biotechnologies, BPZE1 is designed to:
- Block B. pertussis colonization within the nasal passages of adults and children
- Protect adults and children from whooping cough disease
- Potentially prevent transmission, including transmission to vulnerable infants
By preventing nasal colonization, BPZE1 may also interrupt person-to-person transmission, thereby reducing overall pertussis disease incidence within communities. The vaccine’s designation is supported by clinical data from 4 completed clinical trials evaluating BPZE1 in healthy adult populations. BPZE1 was originally developed at the Institut Pasteur de Lille (France) in the laboratory of Camille Locht, PhD, and Nathalie Mielcarek, PhD. The vaccine is currently in Phase II of clinical development for pertussis.
Additional product details and comprehensive drug profiles are provided in the full report.
Learn more about Pertussis drug development opportunities in our groundbreaking research and development analysis @ Pertussis Unmet Needs
What the Report Covers
- Company-Level Insights: Detailed profiles of organizations actively developing Pertussis therapies, including a comprehensive overview of each company’s aggregate therapeutic portfolio.
- Stage-Based Classification: Investigational candidates systematically segmented into early-stage, mid-stage, and late-stage development categories for Pertussis prevention and treatment.
- Active and Inactive Project Tracking: Thorough identification of both active therapeutic initiatives and dormant or discontinued projects across the pipeline landscape.
- Drug Development Analysis: Pipeline drugs organized by development phase, route of administration, target receptor, therapy approach (monotherapy vs. combination), mechanism of action, and molecular classification.
- Collaboration and Financial Assessment: In-depth evaluation of company-company partnerships, company-academia alliances, licensing agreements, acquisitions, mergers, and financing arrangements driving future advancement of the Pertussis market.
Key Pertussis Companies
Tianjin CanSino Biotechnology, ILiAD Biotechnologies, LG Chem, BioNet-Asia, Intravacc, VAXFORM LLC, and other pharmaceutical and biotechnology organizations advancing novel therapeutics and vaccines in the Pertussis pipeline.
Pipeline Coverage by Development Phase
DelveInsight’s report encompasses approximately 10+ products across various clinical development stages, including:
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I)
- Preclinical and Discovery-stage candidates
- Discontinued and Inactive candidates
Therapeutic Assessment by Route of Administration
Pipeline products are classified across multiple delivery methods, including:
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Therapeutic Assessment by Molecule Type
Pertussis pipeline candidates span several molecular categories, including:
- Recombinant fusion proteins
- Small molecules
- Monoclonal antibodies
- Peptides
- Polymers
- Gene therapies
Therapeutic Assessment by Product Type
Pipeline drugs are categorized by therapy approach:
- Monotherapy
- Combination
- Mono/Combination
Stay informed about how emerging therapies are transforming the future of Pertussis prevention and treatment @ Pertussis Market Drivers and Barriers, and Future Perspectives
Report Scope
- Geographic Coverage: Global
- Pertussis Companies: Tianjin CanSino Biotechnology, ILiAD Biotechnologies, LG Chem, BioNet-Asia, Intravacc, VAXFORM LLC, and others
- Pertussis Pipeline Therapies: DTcP Infant, BPZE1, and additional investigational candidates
- Therapeutic Assessment by Product Type: Monotherapy, Combination, Mono/Combination
- Therapeutic Assessment by Clinical Stage: Discovery, Preclinical, Phase I, Phase II, Phase III
For a detailed overview of the latest research findings and future development plans, access the full Pertussis Pipeline Report @ Pertussis Emerging Drugs and Companies
Table of Contents
- Introduction
- Executive Summary
- Pertussis Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Pertussis – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Mid Stage Products (Phase II)
- Early Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Inactive Products
- Pertussis Key Companies
- Pertussis Key Products
- Pertussis Unmet Needs
- Pertussis Market Drivers and Barriers
- Pertussis Future Perspectives and Conclusion
- Pertussis Analyst Views
- Appendix
About DelveInsight
DelveInsight is a premier healthcare-focused market research and consulting firm dedicated to delivering high-quality market intelligence and strategic analysis that supports well-informed business decisions. Backed by a team of experienced industry specialists with deep expertise across the life sciences and healthcare sectors, DelveInsight offers customized research solutions and actionable insights to organizations worldwide. Connect with us to access accurate, real-time intelligence that positions you ahead of the growth curve.
Contact Us
Kanishk
